DR-429 Structural Variation Signatures and ABC transporters in Ovarian Cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-429 Structural Variation Signatures and ABC transporters in Ovarian Cancer
This project explores the genomic heterogeneity of high-grade serous ovarian carcinoma (HGSC) by developing a method to identify structural variation …
DR-421 Molecular functions of steroid hormones in promoting prostate cancer progression
Prostate cancer relies on steroid hormones for development and progression. Hence, targeting steroid hormone pathways by androgen deprivation therapy (ADT) …
DR-412 Breast cancer with APOBEC mutagenesis evolve during progression
APOBEC mutagenesis are more profoundly present in metastatic breast cancer, particularly in ER+/HER2- breast cancer. This suggests that APOBEC driven …
DR-413 Identifying non-coding driver regions in cancer using Machine Learning
Patients with some types of cancer can have their tumor DNA sequenced to identify tumor variants. The identification of specific …
DR-366 The biomarker landscape of metastatic cance
In this project, we will perform a detailed assessment of tumor DNA and RNA characteristics that predict if patients with …
DR-408 Integrative discovery of genomic and transcriptomic drivers of pan-cancer metastatic phenotypes
Cancer is driven by mutations in DNA that activate cancer-causing genes and disable protective genes, causing cells to grow infinitely. …
DR-414 Neoantigen discovery and validation for therapeutic vaccine development
Developing effective cancer therapies is challenging, often benefiting only specific patient groups. The Oncode Accelerator consortium aims to innovate this …
DR-376 Clinical and Functional Interpretation of Whole Genome Sequencing
This project will examine how whole genome sequencing (WGS) may improve the diagnosis and treatment of cancer. First, we will …
DR-416 Mutational signatures of Topoisomerase I poisons in cancer cell models and human tumours
DNA Topoisomerase 1 (Top1) relieves DNA supercoils. Top1 poisons, such as irinotecan, inhibit Top1 DNA religation activity causing DNA breaks, …
DR-401 IMPACT-HPB: Integrative Machine learning for Predictive Assessment and Customized Treatment in Hepato-Pancreato-Biliary Cancers
Hepato-pancreato-biliary (HPB) cancers pose a significant oncological challenge with high mortality rates. Despite diagnostic and therapeutic advancements, prognosis remains poor, …
DR-358 Spatial and longitudinal heterogeneity of liver tumors across ages shaped by interaction between genetics and environment
We aim to decipher the clonal and phenotypic evolution of liver tumors based on genomic analysis of large cohorts (our …
DR-419 Characterizing the role of cytidine deaminase in cancer progression and metastasis
The incidence of cancer is a major health problem worldwide, however the mechanistic basis of cancer development and intervention to …
We willen het maximum aan informatie uit de tumor van de patiënt halen. Deze DNA-test is daarvoor het best beschikbare instrument. Er is maar één keer weefsel, een biopt, met voldoende tumorcellen nodig. Omdat het hele genoom wordt onderzocht, ook de gebieden in het DNA waarvan we nu nog niet weten of de gevonden afwijkingen belangrijk zijn, is deze DNA-test tumortype onafhankelijk en toekomstbestendig. Deze eigenschappen zijn de twee belangrijkste eigenschappen van WGS.